Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the seven analysts that are presently covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation and six have given a buy recommendation to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $33.3333.
CRVS has been the subject of a number of analyst reports. Wall Street Zen cut shares of Corvus Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. The Goldman Sachs Group initiated coverage on shares of Corvus Pharmaceuticals in a research report on Friday, April 17th. They set a “buy” rating and a $40.00 price target on the stock. Finally, Weiss Ratings lowered shares of Corvus Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, July 10th.
View Our Latest Analysis on CRVS
Corvus Pharmaceuticals Stock Up 2.6%
Corvus Pharmaceuticals (NASDAQ:CRVS – Get Free Report) last issued its earnings results on Thursday, May 7th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.01). As a group, equities research analysts anticipate that Corvus Pharmaceuticals will post -0.7 earnings per share for the current fiscal year.
Insider Activity at Corvus Pharmaceuticals
In other news, Director David Scott Moore purchased 21,700 shares of the company’s stock in a transaction on Thursday, June 11th. The shares were purchased at an average price of $11.53 per share, with a total value of $250,201.00. Following the purchase, the director directly owned 21,700 shares of the company’s stock, valued at $250,201. This trade represents a ∞ increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 19.70% of the stock is currently owned by insiders.
Institutional Trading of Corvus Pharmaceuticals
A number of institutional investors have recently made changes to their positions in CRVS. Tema ETFs LLC boosted its holdings in Corvus Pharmaceuticals by 26.4% during the second quarter. Tema ETFs LLC now owns 136,276 shares of the company’s stock worth $2,036,000 after purchasing an additional 28,501 shares during the last quarter. Avity Investment Management Inc. increased its stake in Corvus Pharmaceuticals by 11.9% in the 2nd quarter. Avity Investment Management Inc. now owns 37,150 shares of the company’s stock valued at $555,000 after buying an additional 3,950 shares during the last quarter. Seven Fleet Capital Management LP acquired a new stake in Corvus Pharmaceuticals in the 1st quarter valued at $1,213,000. Perceptive Advisors LLC lifted its position in Corvus Pharmaceuticals by 231.1% during the 1st quarter. Perceptive Advisors LLC now owns 2,292,441 shares of the company’s stock worth $33,538,000 after buying an additional 1,600,000 shares in the last quarter. Finally, Avidity Partners Management LP bought a new stake in Corvus Pharmaceuticals during the 1st quarter worth about $1,682,000. Institutional investors own 46.64% of the company’s stock.
Corvus Pharmaceuticals Company Profile
Corvus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation immuno-oncology therapies. The company’s research efforts are centered on harnessing both the innate and adaptive immune systems to counteract tumor-driven immunosuppression. By targeting key pathways that regulate immune cell function, Corvus aims to create novel agents that can be combined with existing cancer treatments to improve patient outcomes.
Corvus’s lead pipeline candidates include small-molecule and antibody therapies designed to inhibit the adenosine pathway, a known mediator of tumor immune escape.
Featured Articles
- Five stocks we like better than Corvus Pharmaceuticals
- Confidence Is Back, But Earnings Show the Consumer Is Being Picky
- AeroVironment’s Stock Is Down, But Drone Demand Is Taking Off
- 3M’s Redemption Arc: Can Q2 Earnings Change the Narrative?
- 3 Photonics Companies Making Quantum Tech Possible
Receive News & Ratings for Corvus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
